Intra-Cellular Therapies' lead drug, lumateperone (Caplyta), demonstrated successful results in treating major depressive disorder, causing shares to rise 24%.
Intra-Cellular Therapies, a New York-based drugmaker, saw its shares rise 24% as its lead drug, lumateperone (Caplyta), demonstrated successful results in treating major depressive disorder. Already approved for schizophrenia and bipolar depression, the drug's potential new market could benefit from the 21 million Americans experiencing a major depressive episode in 2021. A second late-stage study is expected in Q2 this year.
April 16, 2024
4 Articles